New drug combo aims to shrink Hard-to-Treat lung and throat cancers
NCT ID NCT05956587
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests two drugs, SI-B003 and BL-B01D1, alone or together in 121 adults with advanced non-small cell lung cancer or nasopharyngeal carcinoma. The goal is to see if the combination shrinks tumors and to find the safest, most effective dose. Participants must have tried other treatments and have a life expectancy of at least 3 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SI-B003 and BL-B01D1 (izalontamab brengitecan) given by IV
- What this could lead to
- If successful, this could offer a new treatment option for people with advanced lung or nasopharyngeal cancers that have not responded to other therapies.
- What could go wrong
- This is an early phase II trial with only 121 participants, so results may not apply to everyone. The combination may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chongqing University Cancer Hospital
NOT_YET_RECRUITINGChongqing, Chongqing Municipality, China
-
Fujian Cancer Hospital
NOT_YET_RECRUITINGFuzhou, Fujian, China
-
Henan Cancer Hospital
NOT_YET_RECRUITINGZhengzhou, Henan, China
-
Hunan Cancer Hospita
NOT_YET_RECRUITINGChangsha, Hunan, China
-
Linyi Cancer Hospital
RECRUITINGLinyi, Shangdong, China
-
Liuzhou People's Hospital
NOT_YET_RECRUITINGLiuzhou, Guangxi, China
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
NOT_YET_RECRUITINGGuangzhou, Guangdong, China
-
Sun Yat-sen University Cancer Center
NOT_YET_RECRUITINGGuangzhou, Guangdong, 510000, China
-
The First Affiliated Hospital of Henan University of Science and Technology
NOT_YET_RECRUITINGLuoyang, Henan, China
-
The First Affiliated Hospital of Xi'an Jiao Tong University
NOT_YET_RECRUITINGXi’an, Shanxi, China
-
The First Affiliated Hospital, Sun Yat-sen University
NOT_YET_RECRUITINGGuangzhou, Guangdong, China
-
The Second Affiliated Hospital Of Nanchang University
NOT_YET_RECRUITINGNanchang, Jiangxi, China
-
Tianjin Medical University General Hospital
NOT_YET_RECRUITINGTianjin, Tianjin Municipality, China
-
Union Hospital Tongji Medical College， Huazhong University of Science and Technology
NOT_YET_RECRUITINGWuhan, Hubei, China
-
Zhejiang Cancer Hospital
NOT_YET_RECRUITINGHangzhou, Zhejiang, China
-
Zhongnan Hospital of Wuhan University
NOT_YET_RECRUITINGWuhan, Hubei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?